{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.4","upperLimit":"33.9","value":"21.1"},{"groupId":"OG001","lowerLimit":"30.0","upperLimit":"52.7","value":"41.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"title":"<1% PD-L1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.6","upperLimit":"49.7","value":"43.1"},{"groupId":"OG001","lowerLimit":"38.9","upperLimit":"52.5","value":"45.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"219"}],"units":"Participants"}],"title":"≥1% PD-L1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"297"}],"units":"Participants"}],"description":"PD-L1 Expression is defined as the percent of tumor cells membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 immunohistochemistry (IHC) assay. This is referred to as quantifiable PD-L1 expression and efficacy is determined by objective response rate (ORR) analysis. ORR is defined as the percentage of participants who achieve a best overall response of complete response (CR) or partial response (PR) per Blinded Independent Central Review (BICR) assessments. Per adapted m-RECIST for pleural mesothelioma, each single tumor measurement must be at least 10 mm in length to qualify as measureable disease and contribute to the sum that defines the pleural uni-variate measure.\n\nper RECIST 1.1 for solid tumors, confirmation of response required: CR=Disappearance of all target lesions; PR=At least a 30% decrease in the sum of the Total Tumor Measurement; Progressive disease (PD)=At least a 20% increase in the sum of the Total Tumor Measurement.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV Q2W + Ipilimumab 1 mg/kg IV Q6W","id":"OG000","title":"Treatment A"},{"description":"Pemetrexed 500 mg/m\\^2 + Cisplatin 75 mg/m\\^2 or Carboplatin 5 AUC up to 6 cycles","id":"OG001","title":"Treatment B"}],"paramType":"NUMBER","populationDescription":"All PD-L1 evaluable participants with baseline expression \\<1% or ≥1%","reportingStatus":"POSTED","timeFrame":"From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months)","title":"Objective Response Rate (ORR) According to PD-L1 Expression Level","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}